318 related articles for article (PubMed ID: 28320767)
21. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
Carrier M; Leblanc MH; Perrault LP; White M; Doyle D; Beaudoin D; Guertin MC
J Heart Lung Transplant; 2007 Mar; 26(3):258-63. PubMed ID: 17346628
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Induction Therapy in Kidney Transplantation: A Network Meta-Analysis.
Hwang SD; Lee JH; Lee SW; Park KM; Kim JK; Kim MJ; Song JH
Transplant Proc; 2018 May; 50(4):987-992. PubMed ID: 29731098
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up.
Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
Transpl Immunol; 2017 Feb; 40():42-50. PubMed ID: 27888093
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database.
Jindal RM; Das NP; Neff RT; Hurst FP; Falta EM; Elster EA; Abbott KC
Am J Nephrol; 2009; 29(6):501-8. PubMed ID: 19060477
[TBL] [Abstract][Full Text] [Related]
25. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
26. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
27. Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience.
Jarmi T; Abdelmoneim Y; Li Z; Jebrini A; Elrefaei M
Transpl Immunol; 2023 Apr; 77():101778. PubMed ID: 36584928
[TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
29. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up.
Mangus RS; Fridell JA; Vianna RM; Kwo PY; Chen J; Tector AJ
Liver Transpl; 2012 Jul; 18(7):786-95. PubMed ID: 22237953
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction
.
Descourouez JL; Jorgenson MR; Parajuli S; Mandelbrot DA; Leverson GE; Odorico JS; Redfield RR
Clin Nephrol; 2020 Feb; 93(2):77-84. PubMed ID: 31670651
[TBL] [Abstract][Full Text] [Related]
32. Rabbit antithymocyte globulin induction therapy in adult renal transplantation.
Hardinger KL
Pharmacotherapy; 2006 Dec; 26(12):1771-83. PubMed ID: 17125438
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
[TBL] [Abstract][Full Text] [Related]
34. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients.
Taber DJ; McGillicuddy JW; Bratton CF; Rohan VS; Nadig S; Dubay D; Baliga PK
Ann Surg; 2017 Sep; 266(3):450-456. PubMed ID: 28654544
[TBL] [Abstract][Full Text] [Related]
35. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
Sampaio MS; Chopra B; Sureshkumar KK
Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
[TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
; Haynes R; Harden P; Judge P; Blackwell L; Emberson J; Landray MJ; Baigent C; Friend PJ
Lancet; 2014 Nov; 384(9955):1684-90. PubMed ID: 25078310
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
Kaufman DB; Leventhal JR; Gallon LG; Parker MA
Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317
[TBL] [Abstract][Full Text] [Related]
38. Assessment of immunosuppression induction with basiliximab compared to antithymocyte-globulin in adult heart transplant patients.
Eberhardt TE; Kim DH; Nethersole S; Pearson GJ
Clin Transplant; 2024 Jun; 38(6):e15332. PubMed ID: 38804609
[TBL] [Abstract][Full Text] [Related]
39. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection.
van der Zwan M; Clahsen-Van Groningen MC; van den Hoogen MWF; Kho MML; Roodnat JI; Mauff KAL; Roelen DL; van Agteren M; Baan CC; Hesselink DA
Front Immunol; 2020; 11():1332. PubMed ID: 32719676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
